@article {879, title = {Costs for heart failure with normal vs reduced ejection fraction.}, journal = {Arch Intern Med}, volume = {166}, year = {2006}, month = {2006 Jan 09}, pages = {112-8}, abstract = {

BACKGROUND: Among the elderly population, heart failure (HF) with normal ejection fraction (EF) is more common than classic HF with low EF. However, there are few data regarding the costs of HF with normal EF. In a prospective, population-based cohort of elderly participants, we compared the costs and resource use of patients with HF and normal and reduced EF.

METHODS: A total of 4549 participants (84.5\% white; 40.6\% male) in the National Heart, Lung, and Blood Institute Cardiovascular Health Study were linked to Medicare claims from 1992 through 1998. By protocol echo examinations or clinical EF assessments, 881 participants with HF were characterized as having abnormal or normal EF. We applied semiparametric estimators to calculate mean costs per subject for a 5-year period.

RESULTS: There were 495 HF participants with normal EF (186 prevalent at study entry and 309 incident during the study period) and 386 participants with abnormal EF (166 prevalent and 220 incident). Participants with abnormal EF had more cardiology encounters and cardiac procedures. However, compared with abnormal EF participants, the 5-year costs for normal EF participants were similar in both the prevalent ($33,023 with abnormal EF and $32,580 with normal EF; P=.93) and incident ($49,128 with abnormal EF and $45,604 with normal EF; P=.55) groups. In models accounting for comorbid conditions, the costs with normal and abnormal EF remained similar.

CONCLUSIONS: Over a 5-year period, patients with HF and normal EF consume as many health care resources as those with reduced EF. These data highlight the substantial financial burden of HF with normal EF among the elderly population.

}, keywords = {Aged, Aged, 80 and over, Comorbidity, Echocardiography, Health Care Costs, Heart Failure, Humans, Incidence, Medicare, Prevalence, Prospective Studies, Regression Analysis, Statistics, Nonparametric, Stroke Volume, Systole, United States, Ventricular Function, Left}, issn = {0003-9926}, doi = {10.1001/archinte.166.1.112}, author = {Liao, Lawrence and Jollis, James G and Anstrom, Kevin J and Whellan, David J and Kitzman, Dalane W and Aurigemma, Gerard P and Mark, Daniel B and Schulman, Kevin A and Gottdiener, John S} } @article {938, title = {Long-term costs and resource use in elderly participants with congestive heart failure in the Cardiovascular Health Study.}, journal = {Am Heart J}, volume = {153}, year = {2007}, month = {2007 Feb}, pages = {245-52}, abstract = {

BACKGROUND: Although heart failure (HF) afflicts nearly 5 million Americans, the long-term cost of HF care has not been described previously. In a prospective, longitudinal cohort of community-dwelling elderly from 4 regions, we examined the long-term costs and resource use of elderly patients with HF.

METHODS: We linked 4860 elderly participants in the National Heart, Lung, and Blood Institute Cardiovascular Health Study to Medicare part A and part B claims from 1992 to 2003. Costs were calculated from Medicare payments and discounted at 3\% annually. We applied nonparametric estimators to calculate mean costs and resource use per patient for a 10-year period. To describe the relationship between patient characteristics and long-term costs, we constructed censoring-adjusted regression models.

RESULTS: There were 343 participants (84.8\% white; 50.1\% men; mean age, 78.2 years) with prevalent HF and 4517 participants without HF at study entry. Mean follow-up was 6.7 years (median, 6.4 years). The 10-year survival rates were 33\% and 63\% for the prevalent HF and nonprevalent HF groups (P < .001), respectively. The mean 10-year medical costs were significantly higher for the prevalent HF cohort (54,704 dollars vs 41 dollars,780, P < .001). The higher costs associated with HF were also reflected in greater resource use with more hospitalizations (P < .05) and more intensive care unit days (P < .05). Participants with HF had more physician visits (P < .05), with most of these encounters involving noncardiology physicians. However, in multivariate models, prevalent HF was not an independent predictor of higher costs.

CONCLUSION: Patients with HF consume substantially more health care resources than their elderly peers, and these higher costs persist through 10 years of follow-up. Many of these costs may be related to other comorbid conditions.

}, keywords = {Aged, Costs and Cost Analysis, Female, Health Resources, Heart Failure, Humans, Male, Medicare, Prospective Studies, Time Factors}, issn = {1097-6744}, doi = {10.1016/j.ahj.2006.11.010}, author = {Liao, Lawrence and Anstrom, Kevin J and Gottdiener, John S and Pappas, Paul A and Whellan, David J and Kitzman, Dalane W and Aurigemma, Gerard P and Mark, Daniel B and Schulman, Kevin A and Jollis, James G} } @article {999, title = {Pancreatic beta-cell function as a predictor of cardiovascular outcomes and costs: findings from the Cardiovascular Health Study.}, journal = {Curr Med Res Opin}, volume = {24}, year = {2008}, month = {2008 Jan}, pages = {41-50}, abstract = {

OBJECTIVE: To explore relationships between beta-cell function and incident cardiovascular events, death, and medical costs among elderly individuals.

RESEARCH DESIGN AND METHODS: In a prospective, population-based cohort of 4555 elderly individuals, we examined the effect of beta-cell function on incident cardiovascular events and mortality. We also examined costs for 3715 of these individuals. We used the computer-based homeostasis model assessment (HOMA) to calculate indices of beta-cell function (HOMA-\%B) and insulin sensitivity (HOMA-\%S) using baseline fasting glucose and insulin levels. All subjects were followed from 1992/1993 for 6 years or until death.

MAIN OUTCOME MEASURES: Discrete-time survival model of the effects of beta-cell function on incident cardiovascular events and all-cause mortality; and semiparametric estimators for calculations of mean 6-year costs.

RESULTS: Controlling for HOMA-\%S, a 20\% decrease in HOMA-\%B was associated with increased odds of incident cardiovascular events (odds ratio [OR], 1.09; 95\% confidence interval [CI], 1.05-1.14) and death (OR, 1.10; 95\% CI, 1.07-1.14). The relationships persisted after controlling for clinical and sociodemographic confounders. A 20\% decrease in HOMA-\%B was also associated with increased costs (cost ratio, 1.03; 95\% CI, 1.01-1.05). The significant association did not persist after controlling for confounders.

LIMITATIONS: The sample comprises relatively healthy elderly individuals and is based on data from 1992 through 1999, which may not reflect current experience. The measure of beta-cell function is an estimate generated from single measures of glucose and insulin.

CONCLUSIONS: Beta-cell function as measured by HOMA-\%B is a significant predictor of incident cardiovascular events and mortality but not of costs, controlling for HOMA-\%S and sociodemographic and clinical confounders.

}, keywords = {Aged, Aged, 80 and over, Cardiovascular Diseases, Cohort Studies, Coronary Disease, Female, Follow-Up Studies, Health Care Costs, Heart Failure, Humans, Insulin-Secreting Cells, Male, Myocardial Infarction, Outcome Assessment, Health Care, Prognosis, Prospective Studies, Stroke}, issn = {1473-4877}, doi = {10.1185/030079908x253573}, author = {Curtis, Lesley H and Hammill, Bradley G and Bethel, M Angelyn and Anstrom, Kevin J and Liao, Lawrence and Gottdiener, John S and Schulman, Kevin A} }